|
Glaxo, Theravance File Asthma Drug Application with FDA
NASDAQ LONDON–GlaxoSmithKline PLC (GSK.LN) and Theravance Inc. ( THRX ) have submitted a supplemental new drug application to the U.S. Food and Drug Administration for a drug used for treatment of asthma in patients aged 12 years and older. The British … GSK and Theravance Announce Submission to US Regulatory Authorities for … Glaxo And Theravance Submits Supplemental NDA For Breo Ellipta |
View full post on asthma – Google News